Immatics (NASDAQ: IMTX – Get Rating) and PharmaCyte Biotech (OTCMKTS: PMCB – Get Rating) are both small cap medical companies, but what is the best investment? We will compare the two companies based on the strength of analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.
Institutional and privileged property
36.6% of Immatics shares are held by institutional investors. Comparatively, 10.9% of PharmaCyte Biotech’s shares are held by institutional investors. Strong institutional ownership indicates that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current valuations and target prices for Immatics and PharmaCyte Biotech, as reported by MarketBeat.com.
|Sell ratings||Keep the ratings||Buy ratings||Strong purchase ratings||Evaluation score|
Immatics currently has a consensus price target of $ 25.00, indicating a potential upside of 263.37%. Given Immatics’ stronger consensus rating and possible higher hike, equity research analysts clearly believe Immatics is more favorable than PharmaCyte Biotech.
Evaluation and earnings
This table compares the gross revenues, earnings per share (EPS) and valuation of Immatics and PharmaCyte Biotech.
|Gross Income||Price / sales ratio||Net income||Earning per share||Price / earnings ratio|
|Immatic||$ 41.13 million||10.52||– $ 110.43 million||($ 1.68)||-4.10|
|PharmaCyte Biotech||N / A||N / A||– $ 3.55 million||N / A||N / A|
PharmaCyte Biotech has lower revenue, but higher earnings than Immatics.
This table compares Immatics and PharmaCyte Biotech’s net margins, return on equity and return on assets.
|Net margins||Return on equity||Return on assets|
|PharmaCyte Biotech||N / A||-7.71%||-7.62%|
Risk and volatility
Immatics has a beta of 0.38, which means its share price is 62% less volatile than the S&P 500. By comparison, PharmaCyte Biotech has a beta of -0.03, which means its share price it is 103% less volatile than the S&P 500.
Immatics beats PharmaCyte Biotech on 6 out of 10 factors compared between the two stocks.
About Immatics (Get evaluation)
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor-based (TCR) immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies that focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACTs) and bispecific antibody-like TCRs. Its ACTengine candidate products are in Phase I clinical trials, which include IMA201 which targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 targeting melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung cancer and hepatocellular carcinoma; and IMA203 which targets antigen preferentially expressed in melanoma in adult patients with relapsed and / or refractory solid tumors, as well as IMA204, which is in preclinical studies targeting tumor stroma cells. The company’s TCR Bispecifics candidate products, which are in preclinical studies, include IMA401, a testicular cancer antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, a candidate product for allogeneic cell therapy. The company has a strategic partnership agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center for the development of multiple adoptive cell therapies based on T cells and TCR; Celgene Switzerland LLC to develop new adoptive cell therapies targeting multiple cancers; and Genmab A / S to develop bispecific immunotherapies involving T cells targeting multiple cancer indications. Immatics NV is headquartered in Tübingen, Germany.
About PharmaCyte Biotech (Get evaluation)
PharmaCyte Biotech, Inc., a biotechnology company, focuses on the development and commercialization of cell therapies for cancer and diabetes in the United States. Its cell therapies are developed on the basis of Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform for the treatment of various types of cancer, including advanced non-metastatic pancreatic cancer and inoperable, as well as diabetes. The company is developing therapies for pancreas and other cancers, including encapsulated genetically modified living cells. It is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and cancer therapies based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology in Sydney to create a version of melligene cells for the treatment of diabetes; and the University of Northern Colorado to develop methods for identifying, separating and quantifying the constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was formed in 1996 and is headquartered in Laguna Hills, California.
Receive news and ratings for Immatics every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Immatics and related companies with MarketBeat.com’s FREE daily newsletter.